The dilemma of data-safety monitoring: provision of significant new data to research participants

The Lancet

Volumn 371, Issue 9611, 2008, Pages 527-529

  Peppercorn, Jeffery ^a   Buss, William G ^b   Fost, Norm ^c   Godley, Paul A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA COLLEGE OF LAW   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PLACEBO;

ARTICLE; CLINICAL DECISION MAKING; DATA ANALYSIS; HEALTH CARE COST; INFORMED CONSENT; MEDICAL INFORMATION; MEDICAL RESEARCH; MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; RESEARCH ETHICS; SAFETY;

EID: 38849103688     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60239-1     Document Type: Note

References (20)

1. US Department of Health and Human Services. Code of Federal Regulations, title 45, part 46. Protection of human subjects (2005), Department of Health and Human Services
2. World Medical Association. Declaration of Helsinki (1964). BMJ 313 (1996) 1448-1449
3. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report: appendix vol 1 (1978), US Government Printing Office, Washington, DC
4. The Nuremberg Code. Reprinted in: Trials of war criminals before the Nuernberg Military Tribunals under Control Council Law No. 10 (1949), US Government Printing Office, Washington DC 181-182
5. Emanuel E., Wendler D., and Grady C. What makes clinical research ethical?. JAMA 283 (2000) 2701-2711
6. Joffe S., Cook E., Cleary P., Clark J., and Weeks J. Quality of informed consent: a new measure of understanding among research subjects. J Natl Cancer Inst 93 (2001) 139-147
7. Kodish E., Pentz R., Noll R., Ruccione K., Buckley J., and Lange B. Informed consent in the Childrens Cancer Group: results of preliminary research. Cancer 82 (1998) 2467-2481
8. Daugherty C., Ratain M., Minami H., et al. Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol 16 (1998) 2305-2312
9. Partridge A., Wong J., Knudsen K., et al. Offering participants results of a clinical trial: sharing results of a negative study. Lancet 365 (2005) 963-964
10. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 317 (1987) 141-145
11. Fallowfield L., Jenkins V., Brennan C., Sawtell M., Moynihan C., and Souhami R. Attitudes of patients to randomised clinical trials of cancer therapy. Eur J Cancer 34 (1998) 1554-1559
12. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
13. Thompson I., Goodman P., Tangen C., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
14. Madsen S., Mirza M., Holm S., Hilsted K., Kampmann K., and Riis P. Attitudes towards clinical research amongst participants and nonparticipants. J Intern Med 251 (2002) 156-168
15. Joffe S., Cook E., Clark J., and Weeks J. Altruism among participants in cancer clinical trials. Proc Am Soc Clin Oncol 22 abstr 2103 (2003)
16. Rosenbaum J., Wells C., Viscoli C., Brass L., Kernan W., and Horwitz R. Altruism as a reason for participation in clinical trials was independently associated with adherence. J Clin Epidemiol 58 (2005) 1109-1114
17. Slutsky A., and Lavery J. Data safety and monitoring boards. N Engl J Med 350 (2004) 1143-1147
18. Truog R., Robinson W., Randolph A., and Morris A. Is informed consent always necessary for randomized, controlled trials?. N Engl J Med 340 (1999) 804-807
19. Beauchamp T., and Childress J. Principles of biomedical ethics. 4th edn. (1994), Oxford University Press, New York 148-149
20. Burstein H. Beyond tamoxifen-extending endocrine treatment for early-stage breast cancer. N Engl J Med 349 (2003) 1857-1859